Journal of Enzyme Inhibition and Medicinal Chemistry (Dec 2023)

1,2,3-Benzoxathiazine-2,2-dioxides – effective inhibitors of human carbonic anhydrases

  • Jekaterina Ivanova,
  • Morteza Abdoli,
  • Alessio Nocentini,
  • Raivis Žalubovskis,
  • Claudiu T. Supuran

DOI
https://doi.org/10.1080/14756366.2022.2142787
Journal volume & issue
Vol. 38, no. 1
pp. 225 – 238

Abstract

Read online

AbstractA series of 1,2,3-benzoxathiazine-2,2-dioxides possessing various substituents in the 5, 7, or 8 position was obtained from corresponding 2-hydroxybenzaldehydes in their reaction with sulfamoyl chloride. 5-, 7-, and 8-aryl substituted 1,2,3-benzoxathiazine-2,2-dioxides were prepared from aryl substituted 2-hydroxybenzaldehydes obtained from 3-, 4-, or 6-bromo-2-hydroxybenzaldehydes via two-step protocol. 1,2,3-Benzoxathiazine-2,2-dioxides were investigated for the inhibition of four human carbonic anhydrase (hCA, EC 4.2.1.1) isoforms, cytosolic hCA I and II and tumour-associated transmembrane hCA IX and XII. Twenty four derivatives of 1,2,3-benzoxathiazine 2,2-dioxide were obtained. Most of them act as nanomolar inhibitors of hCA IX and XII. Almost all compounds except 2d and 5a-e also express nanomolar inhibitory activity for hCA II. hCA I is poorly inhibited or not inhibited by 1,2,3-benzoxathiazine 2,2-dioxides. Some of the new derivatives exhibit promising selectivity towards CA IX/XII over hCA I, although none of the compounds are selective towards CA IX/XII over both hCA I and II.

Keywords